CoChat

Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model

Pastuskovas, Cinthia V., Mundo, Eduardo E., Williams, Simon P., Nayak, Tapan K., Ho, Jason, Ulufatu, Sheila, Clark, Suzanna, Ross, Sarajane, Cheng, Eric, Parsons-Reponte, Kathryn, Cain, Gary, Van Hoy, Marjie, Majidy, Nicholas, Bheddah, Sheila, dela Cruz Chuh, Josefa, Kozak, Katherine R., Lewin-Koh, Nicholas, Nauka, Peter, Bumbaca, Daniela, Sliwkowski, Mark, Tibbitts, Jay, Theil, Frank-Peter, Fielder, Paul J., Khawli, Leslie A., Boswell, C. Andrew · 2012 · Molecular Cancer Therapeutics
Cited by 103

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression correlate with aggressive phenotypes and decreased survival among breast cancer patients. Concordantly, the combination of trastuzumab (anti-HER2) with bevacizumab (anti-VEGF) has shown promising results in preclinical xenograft studies and in clinical trials. However, despite the known antiangiogenic mechanism of anti-VEGF antibodies, relatively little is known about their effects on the pharmacokinetics and tissue distribution of other antibodies. This study aimed to measure the disposition properties, with a particular emphasis on tumor uptake, of trastuzumab in the presence or absence of anti-VEGF. Radiolabeled trastuzumab was administered alone or in combination with an anti-VEGF antibody to mice bearing HER2-expressing KPL-4 breast cancer xenografts. Biodistribution, autoradiography, and single-photon emission computed tomography–X-ray computed tomography imaging all showed that anti-VEGF administration reduced accumulation of trastuzumab in tumors despite comparable blood exposures and similar distributions in most other tissues. A similar trend was also observed for an isotype-matched IgG with no affinity for HER2, showing reduced vascular permeability to macromolecules. Reduced tumor blood flow (P < 0.05) was observed following anti-VEGF treatment, with no significant differences in the other physiologic parameters measured despite immunohistochemical evidence of reduced vascular density. In conclusion, anti-VEGF preadministration decreased tumor uptake of trastuzumab, and this phenomenon was mechanistically attributed to reduced vascular permeability and blood perfusion. These findings may ultimately help inform dosing strategies to achieve improved clinical outcomes. Mol Cancer Ther; 11(3); 752–62. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0742-t

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 103

Metadata

Authors
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., Cain, G., Van Hoy, M., Majidy, N., Bheddah, S., dela Cruz Chuh, J., Kozak, K. R., Lewin-Koh, N., Nauka, P., Bumbaca, D., Sliwkowski, M., Tibbitts, J., Theil, F.-P., Fielder, P. J., Khawli, L. A., & Boswell, C. A.
Venue
Molecular Cancer Therapeutics
Published
2012-03-01
Volume
11
Issue
3
Pages
752-762
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2112154408
Cited by
103
References
4
FWCI
6.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0742-t
The paper
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., Cain, G., Van Hoy, M., Majidy, N., Bheddah, S., dela Cruz Chuh, J., Kozak, K. R., Lewin-Koh, N., Nauka, P., Bumbaca, D., . . . Boswell, C. A. (2012). Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0742-t

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.